← Leaderboards
Howard Bailey
University Of Wisconsin-Madison
$12,079,664
Attributed
$12,079,664
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.3M · FY2014–22$2.5M$1.9M$1.3M$625K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$12,079,664 · 1
By mechanism
N01$11,568,453 · 1
N02$511,211 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Wisconsin-Madison
Same institution · by research overlap
- Lisa M Barroilhet$6,710,460
- Mark E Burkard$10,864,762
- Kirk Weeks$1,789,737
- Lori E Wright$189,928
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsContractorSafetyOperative Surgical ProceduresDivision Of Cancer PreventionNational Cancer InstituteDoseMalignant NeoplasmsProgramsMonitorMeetingsMolecular TargetCancer PreventionPreventionSitePrevention Clinical TrialTissuesClinically RelevantPreventiveDrug IndustryFundingPerformanceConduct Clinical TrialsInterest
Grant awards (26)
PILOT STUDY OF DAILY EXEMESTANE IN WOMEN WITH COMPLEX ATYPICAL HYPERPLASIA OF THE ENDOMETRIUM/ENDOMETRIAL INTRAEPITHELIAL NEOPLASIA OR GRADE 1 ENDOMETRIAL CANCER$296,637
N02 · FY2022 · CA · contact PI
CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH$107,482
N01 · FY2022 · CA · contact PI
CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH$707,254
N01 · FY2021 · CA · contact PI
PILOT STUDY OF DAILY EXEMESTANE IN WOMEN WITH COMPLEX ATYPICAL HYPERPLASIA OF THE ENDOMETRIUM/ENDOMETRIAL INTRAEPITHELIAL NEOPLASIA OR GRADE 1 ENDOMETRIAL CANCER$107,353
N02 · FY2021 · CA · contact PI
CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH$816,825
N01 · FY2020 · CA · contact PI
PHASE IB 9CUAB30 IN EARLY STAGE BREAST CANCER TO EVALUATE BIOLOGIC EFFECT$271,856
N01 · FY2020 · CA · contact PI
PILOT STUDY OF DAILY EXEMESTANE IN WOMEN WITH COMPLEX ATYPICAL HYPERPLASIA OF THE ENDOMETRIUM/ENDOMETRIAL INTRAEPITHELIAL NEOPLASIA OR GRADE 1 ENDOMETRIAL CANCER$107,221
N02 · FY2020 · CA · contact PI
CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH$822,242
N01 · FY2019 · CA · contact PI
PILOT STUDY OF DAILY EXEMESTANE IN WOMEN WITH COMPLEX ATYPICAL HYPERPLASIA OF THE ENDOMETRIUM/ENDOMETRIAL INTRAEPITHELIAL NEOPLASIA OR GRADE 1 ENDOMETRIAL CANCER$409,406
N01 · FY2019 · CA · contact PI
A Phase I Open Label, Dose Escalation Clinical Trial assessing the Safety, Tolerability, and Feasibility of pNGLV4aCRTE6E7L2 HPV DNA vaccine administration via Intramuscular TriGridTM Ele$946,290
N01 · FY2018 · CA · contact PI
IGF::OT::IGF - CORE INFRASTRUCTURE SUPPORT$834,155
N01 · FY2018 · CA · contact PI
PILOT STUDY OF DAILY EXEMESTANE IN WOMEN WITH COMPLEX ATYPICAL HYPERPLASIA OF THE ENDOMETRIUM/ENDOMETRIAL INTRAEPITHELIAL NEOPLASIA OR GRADE 1 ENDOMETRIAL CANCER$280,420
N01 · FY2018 · CA · contact PI
A PHASE I TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A DNA PLASMID BASED VACCINE (WOKVAC) ENCODING EPITOPES DERIVED FROM THREE BREAST CANCER ANTIGENS (IGFBP-2, HER2, AND IGF-IR) IN PAT$250,081
N01 · FY2018 · CA · contact PI
IGF::OT::IGF - CORE INFRASTRUCTURE SUPPORT$816,237
N01 · FY2017 · CA · contact PI
IGF::OT::IGF PILOT STUDY OF DAILY EXEMESTANE IN WOMEN WITH COMPLEX ATYPICAL HYPERPLASIA OF THE ENDOMETRIUM/ENDOMETRIAL INTRAEPITHELIAL NEOPLASIA OR GRADE 1 ENDOMETRIAL CANCER$277,191
N01 · FY2017 · CA · contact PI
A PHASE I TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A DNA PLASMID BASED VACCINE (WOKVAC) ENCODING EPITOPES DERIVED FROM THREE BREAST CANCER ANTIGENS (IGFBP-2, HER2, AND IGF-IR) IN PAT$251,615
N01 · FY2017 · CA · contact PI
IGF::OT::IGF A Phase I Trial of the Safety and Immunogenicity of RG1-VLP, a candidate broadly protective vaccine for the prevention of HPV-associated cancer$95,414
N01 · FY2017 · CA · contact PI
IGF::OT::IGF A Phase I Open Label, Dose Escalation Clinical Trial assessing the Safety, Tolerability, and Feasibility of pNGLV4aCRTE6E7L2 HPV DNA vaccine administration via Intramuscular TriGridTM Ele$45,458
N01 · FY2017 · CA · contact PI
IGF::OT::IGF - CORE INFRASTRUCTURE SUPPORT$822,413
N01 · FY2016 · CA · contact PI
IGF::OT::IGF PHASE IB 9CUAB30 IN EARLY STAGE BREAST CANCER TO EVALUATE BIOLOGIC EFFECT$692,337
N01 · FY2016 · CA · contact PI
Phase IIB Randomized, Placebo-Controlled Trial of ACTOplus met® XR in Subjects with Stage I-IV Squamous Cell Carcinoma of the Oral Cavity of Oropharynx Prior to Definitive Treatment$554,592
N01 · FY2016 · CA · contact PI
A PHASE I TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A DNA PLASMID BASED VACCINE (WOKVAC) ENCODING EPITOPES DERIVED FROM THREE BREAST CANCER ANTIGENS (IGFBP-2, HER2, AND IGF-IR) IN PAT$55,996
N01 · FY2016 · CA · contact PI
IGF::OT::IGF - CORE INFRASTRUCTURE SUPPORT$806,907
N01 · FY2015 · CA · contact PI
IGF::OT::IGF R&D-A PHASE I TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A DNA PLASMID BASED VACCINE (WOKVAC) ENCODING EPITOPES DERIVED FROM THREE BREAST CANCER ANTIGENS (IGFBP-2, HER2, AND IGF-IR) IN PAT$727,469
N01 · FY2015 · CA · contact PI
IGF::OT::IGF A RANDOMIZED, DOUBLE-BLIND, PHASE I DOSE-ESCALATION STUDY OF THE NOVEL RETINOID 9CUAB30$267,578
N01 · FY2015 · CA · contact PI
CORE INFRASTRUCTURE SUPPORT$709,235
N01 · FY2014 · CA · contact PI